110
Participants
Start Date
August 8, 2018
Primary Completion Date
August 31, 2025
Study Completion Date
September 30, 2025
Bevacizumab
Bevacizumab will be administered by IV infusion at 15mg/kg on Day 1 of every 21-days cycle.
Atezolizumab
Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, loss of clinical benefit as determined by the investigator.
UAB Women and Infants Center, Birmingham
Washington University School of Medicine, St Louis
Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City
Collaborators (1)
Genentech, Inc.
INDUSTRY
University of Oklahoma
OTHER